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Objective To investigate the epidemiology, microbiology and outcome of infections
caused by Capnocytophaga spp. at a single center.
Methods We report on ten documented infectious episodes caused by Capnocytophaga
observed between 1994 and 1999 at the Innsbruck University Hospital.
Results In seven of ten patients, Capnocytophaga septicemia was diagnosed during
periods of neutropenia. In contrast, the remaining three patients had normal white
blood cell counts when acquiring Capnocytophaga septicemia (one) and pleural empyema
(two). Blood cultures containing long, slender, Gram-negative rods, which grew slowly
under anaerobic conditions and lacked susceptibility to metronidazole, were subculti-
vated in a CO2-enriched atmosphere (5%). Subcultivation yielded Capnocytophaga in all
ten cases within 2–12 days. The patients were then placed on appropriate antibiotic
therapy, with or without additional surgical intervention, and the organism was eradi-
cated.
Conclusion Identification of Capnocytophaga facilitates appropriate, and in most cases
effective, antimicrobial therapy.
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I N T R O D U C T I O N
Infections caused by microbes thus far not con-
sidered as pathogens in the normal host have
become a challenging problem in the past decade,
due to an increase in the number of elderly
patients, new medical techniques such as implan-
table devices, and patients suffering from severe
immunosuppression (leukopenia, transplantation,
AIDS, etc.). In the past 15 years, Capnocytophaga
spp. have been recognized as pathogens involved
in a variety of infections in animals and humans
[1,2]. Several case reports and review articles have
described clinical patterns, risk factors, microbio-
logical data and recommendations for proper ther-
apy [3,4]. Some Capnocytophaga strains appear in
the human oropharyngeal flora, and association
with periodontitis is well known [5]. Other strains
inhabit the oropharynx of animals such as dogs,
cats and rats [6]. Most capnocytophaga infections
have therefore been described in neutropenic
patients as endogenous infections [7] or as wound
infections resulting from animal bites or closed-
fist injuries [3]. Owing to toxins, in many cases
infections with this pathogen are severe or life-
threatening [8]. Moreover, Capnocytophaga is fre-
quently isolated as part of a polymicrobial flora [9].
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This article describes a series of capnocytophaga
infections in both immunocompromised and
immunocompetent patients observed in a 6-year
period at the Innsbruck University Hospital.
M A T E R I A L S A N D M E T H O D S
Patients
Hospital records of the 10 patients described in
this article were reviewed in detail. This investiga-
tion includes all systemic capnocytophaga infec-
tions occurring at our hospital during the study
period. Seven of our patients were female, and
three were male; the median age was 42 years
(range: 22–80 years). Isolates were judged as
pathogenic only if recovered from normally sterile
sites (blood, pleural effusion) in patients with
clinical evidence of infection. Concomitant isola-
tion of other pathogens was also recorded. Nine of
the 10 patients in the study were classified as
severely immunocompromised (seven with neu-
tropenia, one with malabsorption syndrome after
bowel resection, and one with Child B liver cir-
rhosis). Demographic data are listed in Table 1.
Processing of clinical specimens
Blood (patients 1–5 and 7–9) and exudates from
surgically drained pleural effusions (patients 6
and 10) were sent for microbiological testing. Spe-
cimens were processed according to methods
described previously [10]. Exudates from surgi-
cally drained pleural effusions were cultured aero-
bically as well as anaerobically. These specimens
were cultured in brain–heart infusion (BHI) broth,
plated on Columbia blood agar plates (BAP)
(Oxoid, Basingstoke, UK) and chocolate agar
plates, and incubated for 48 h aerobically and in
a CO2-enriched atmosphere. Moreover, anaerobic
cultivation was performed using thioglycolate
broth (Oxoid), Schaedler agar (Oxoid), and Bacter-
oides bile esculin agar (BBE) (Oxoid), and incu-
bated anaerobically for 48 h.
Blood culture bottles were processed with BacT
Alert (Organon Teknika, Durham, NC, USA).
Blood culture media bottles for aerobe and anae-
robe cultivation were incubated for up to 5 days,
and aerobic bottles were ventilated at the labora-
tory before incubation. Bottles reported to be posi-
tive were tested further by Gram stain. The Gram
stain of Capnocytophaga reveals long, Gram-nega-
tive, fusiform rods [11]. Subcultivation was per-
formed on BAP (1) under aerobic conditions, (2)
in a CO2-enriched atmosphere (5–10%), and (3)
under anaerobic conditions on Schaedler agar
(Oxoid). Primary identification was carried out
with the RAPID-ANA II System (Innovative Diag-
nostic Systems, Inc., Norcross, GA, USA). Anti-
biotic susceptibility testing was performed with
a disk diffusion technique, using Oxoid disks
according to National Committee for Clinical
Laboratory Standards (NCCLS) guidelines for bac-
teria that grow aerobically, in Mueller–Hinton
agar (Oxoid) with 5% sheep blood. Determination
of minimal inhibitory concentrations (MICs) was
done by Etest (AB-Biodisk, Solnar, Sweden) on
BAP. The NCCLS has not yet provided specific
guidelines for the testing of these organisms.
Seven of the ten isolated strains were subtyped
in a reference laboratory (Colindale, London).
Table 1 Patient demographics
No. CCP ID
Days
to ID
Age
(years) Sex Disease Therapy
Onset
post-SCT
(days)
1 7 May 1994 4 37 M Chronic myelogenous leukemia Stem cell transplantation 9
2 14 August 1994 11 80 F Severe aplastic anemia Cyclosporin A, high-dose Ig NA
3 15 August 1994 4 34 F Chronic myelogenous leukemia Stem cell transplantation 9
4 23 October 1994 10 32 F Acute myelogenous leukemia Stem cell transplantation 6
5 5 January 1995 12 50 F Coagulopathy, mesenteric
thrombosis
Subtotal bowel resection, TPI NA
6 26 January 1995 6 46 F Liver cirrhosis (Childs B) ICU support NA
7 1 July 1995 6 44 F Acute myelogenous leukemia Polychemotherapy NA
8 26 September 1995 8 22 F Recurrent Hodgkin disease Polychemotherapy 8
9 11 March 1997 12 46 M Chronic myelogenous leukemia Stem cell transplantation 8
10 10 March 1999 4 29 M GERD, gingivitis Nissen fundoplication NA
CCP, Capnocytophaga; ID, identification; ICU, intensive care unit; SCT, stem cell transplantation; NA, not applicable; Ig,
immunoglobulin; TPI, total parenteral nutrition; GERD, gastroesophageal reflux disease.
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Molecular biological investigations (restriction
fragment length polymorphism)
Seven Capnocytophaga isolates were available for
further investigation. They were grown in BHI
broth (Becton-Dickinson, Cockeysville, MD, USA)
overnight. Chromosomal DNA was isolated using
a modification (lysocym instead of lysostaphin) of
the method described elsewhere [12]. Three micro-
liters of the final DNA solution was used for the
amplification reaction. Rep-PCR was performed
by using primer RW3A (50-TCGCTCAAAACA-
ACGACACC-30) and Ready-To-Go RAPD Analy-
sis Beads (Pharmacia Biotech, Uppsala, Sweden).
Cycling was carried out in a thermocycler (Gen-
eAmp PCR System 2400, Perkin-Elmer, Norwalk,
CT, USA), and consisted of 3 min at 95 8C and 30
repeats of 1 min at 94 8C, 1 min at 54 8C, and
2 min at 72 8C. Amplified DNA was analyzed
by gel electrophoresis in 2% agarose (Ultrapure;
Gibco BRL, Grand Island, New York, USA) in 1%
Tris-borate–EDTA, pH 8.5, followed by ethidium
bromide staining and photography.
R E S U L T S
Clinical data are summarized in Table 2. Eight
patients developed septicemia, which originated
from the oropharynx due to severe mucositis or
candida thrush in seven cases. A pseudocluster of
four infections was observed in 1994 in stem cell
recipients. Three of them had been treated in the
same laminar airflow unit within a 4-month per-
iod. One patient developed capnocytophaga sep-
ticemia while on the waiting list for small bowel
transplantation. This patient was on total parent-
eral nutrition for a prolonged time after subtotal
resection of necrotic small bowel due to mesenteric
ischemia.
Two patients presented with a pleural empyema.
In the first case, we observed a spontaneous
pleural empyema in a patient suffering from Child
B post-hepatitis C virus liver cirrhosis from whom
Capnocytophaga ochracea, Prevotella melaninogenica
and Milleri streptococci were isolated. In the sec-
ond case, pleural empyema occurred after laparo-
scopic Nissen fundoplication and a subsequent
esophageal lesion in a young patient who suffered
from severe gingivitis. Both pleural empyemas
were mixed infections: the first included Prevotella
spp., peptostreptococci and Streptococcus inter-
medius (Milleri group), and the second included
viridans streptococci and enterococci. Both cases
have been described in detail elsewhere [13,14].
Polymicrobial infection was evident in five cases,
and consisted of viridans streptococci, Prevotella
spp., peptostreptococci, enterococci, Milleri group
streptococci, coagulase-negative staphylococci,
and Candida albicans (Table 2).
The isolated strains showed resistance to ami-
noglycosides, metronidazole, and glycopeptides,
and susceptibility to b-lactam antibiotics, carbape-
nems, tetracyclines, macrolides, clindamycin, and
co-trimoxazole (Figure 1). Eight patients had been
pretreated empirically with a second- or third-
generation cephalosporin (six in combination with
other antibiotics: aminoglycoside plus glycopep-
tide (four), glycopeptide (one), metronidazole
(one)), and two patients with a quinolone. In only
one case was second-generation cephalosporin
treatment successful. In the remaining nine cases,
a change to penicillin G (one), piperacillin–tazo-
bactam (one), imipenem–cilastatin (six) or clinda-
mycin plus penicillin G (one) resulted in clinical
improvement. All capnocytophaga infections res-
ponded to therapy. Five of the ten patients died
due to complications connected with their under-
lying diseases within 6 months after successful
treatment of capnocytophaga infection. Patients
4 (follow-up 70 months) and 6 (follow-up
67 months) are still alive, with no signs of rec-
urrence of their hematologic disorders (acute
myelogenous leukemia (stem cell transplant)
and Hodgkin’s disease, respectively). Patient 8
received a liver transplant 2 weeks after capnocy-
tophaga pleural effusion. She is still alive (follow-
up 59 months). Patient 9 is in remission after
unrelated bone marrow transplant for chronic
myelogenous leukemia (follow-up 42 months).
Patient 10 is alive 18 months after laparoscopic
antireflux surgery, which was complicated by
capnocytophaga pleural empyema.
The median time from specimen collection to
identification of Capnocytophaga was 7 days (range:
4–12 days. There was no difference between the
eight blood samples and the two pleural effusion
samples with regard to time required for initial
growth. Capnocytophaga grew on BAP under sub-
cultivation in a CO2-enriched atmosphere and
under anaerobic subcultivation. Subcultivation
yielded Capnocytophaga in all 10 cases within 2–
12 days. Figure 2 shows a Gram stain of Capnocy-
tophaga from a blood culture taken after 48 h
of cultivation under anaerobic conditions. The
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Table 2 Clinical parameters
No. NP Mucositis
Clinical
presentation
Concomitant
isolates
Empirical
pretreatment
Therapy of
CCP infection
Follow-up
May 2002 Cause of death
1 Yes Yes Sepsis Streptococcus
sanguis
Cefandamole,
amikazin
vancomycin
Imipenem–cilastatin,
PenG
11.1994 CMV disease
2 Yes No Sepsis 0 Cefamandole,
vancomycin
PenG 8.1994 MOF
3 Yes Yes Sepsis CNS Cefamandole,
tobramycin,
vancomycin
Piperacillin–tazobactam 1.1995 GvH disease
4 Yes Yes Sepsis 0 Cefamandole,
amikacin
vancomycin
Imipenem–cilastatin Alive NA
5 No No, candida
thrush
Sepsis Candida
albicans
Cefuroxime Imipenem–cilastatin 1.1995 MOF
6 No No Pleural
effusion
Streptococcus
intermedius,
Prevotella spp.
Ciprofloxacin Imipenem–cilastatin Alive NA
7 Yes Yes Sepsis 0 Ciprofloxacin Cefamandole,
tobramycin
1.1996 Aspergillosis
8 Yes Yes, candida
thrush
Sepsis 0 Cefamandole,
amikacin,
teicoplanin
Imipenem–cilastatin Alive NA
9 Yes Yes Sepsis 0 Cefamandole Imipenem–cilastatin Alive NA
10 No No Pleural
empyema
Viridans
streptococci,
peptostreptococci
Cefotaxime,
metronidazole
Clindamycin,
PenG,
fosfomycin
Alive NA
NP, neutropenia; CCP, Capnocytophaga; CMV, cytomegalovirus; GvH, graft-versus-host disease; PenG, penicillin G; NA, not applicable; CNS, coagulase-negative
staphylococci; MOF, multi-organ failure.
Date of death.
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isolated strains were oxidase and catalase nega-
tive, and did not grow on MacConkey agar. These
facultatively anaerobic isolates fermented glucose,
sucrose, lactose and maltose. Four strains exhib-
ited gliding motility, and four strains produced
pigmented (yellow–orange) colonies. No pseudo-
pitting growth was observed. All strains were
starch-hydrolysis and ONPG-hydrolysis positive,
and gelatin liquefaction test negative.
Speciation of seven strains, including three iso-
lates from stem cell recipients treated consecu-
tively in the same laminar airflow unit during
a period of 4 months in a reference laboratory
(Collindale, UK), revealed that all isolates were
Capnocytophaga ochracea. These seven strains were
also tested by pulsed-field gel electrophoresis
(Figure 3). Restriction fragment length poly-
morphism (RFLP) of Capnocytophaga DNA using
blabla as the restriction enzyme revealed different
patterns of DNA banding, indicating that the ser-
ies of capnocytophaga infections described here
was not derived from one source. Hence, a com-
mon source for infection can be excluded, and we
suggest that these infections were endogenous,
deriving from the patients’ own oral flora. The
remaining three Capnocytophaga isolates were not
available for speciation.
D I S C U S S I O N
The spectrum of microorganisms causing infec-
tions in the immunocompromised host is expand-
ing. Anaerobic and micro-aerophilic bacteria
previously considered harmless have now been
recognized as pathogens [15–17]. Such organisms
can cause severe infections, especially after solid
organ or hematopoietic stem cell transplantation,
or if introduced into otherwise sterile sites, such as
during surgical procedures.
Invasive capnocytophaga infections have been
reported in immunocompromised patients and in
the normal host after animal bites [3,4,8]. At our
own center, nine of ten cases of capnocytophaga
infection between 1994 and 1999 were seen in
severely immunosuppressed patients. In seven
cases, neutropenia after high-dose chemotherapy
Figure 1 MICs of various antibiotics
against Capnocytophaga.
Figure 2 Result of RFLP. Lane 1, ladder; lane 2, patient 1;
lane 3, patient 3; lane 4, patient 3; lane 5, patient 4; lane 6,
patient 7, strain 1 (blood culture I); lane 7, patient 7, strain 2
(blood culture II); lane 8, patient 8; lane 9, negative control;
lane 10, ladder. Strains of the remaining patients were not
available.
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for hematologic malignancy was present. Neutro-
penia and oral mucositis are the most important
risk factors predisposing to bloodstream infection
with the genus [7]. Patients with other conditions
associated with immunosuppression, such as
short bowel syndrome and end-stage liver disease
(patients 5 and 6), also appear to be prone to
capnocytophaga infection. In such cases, the
patients may be unable to defend themselves as
a normal host would against spontaneous bacter-
emia, thus resulting in invasive disease.
More recently, capnocytophaga infections in
immunocompetent patients have been reported.
Parenti and Snydmann [9] describe one case of
capnocytophaga empyema occurring in an immu-
nocompetent patient with traumatic rupture of the
proximal esophagus from a motor vehicle acci-
dent. This case bears a resemblance to patient 10
in our series, who was also immunocompetent,
and who developed capnocytophaga pleural
empyema after laparoscopic Nissen fundoplica-
tion, associated with an iatrogenic esophageal
miniperforation. Notably, our patient suffered
from severe gingivitis. Capnocytophaga is rarely
reported after esophageal injuries. Owing to diffi-
culties in the isolation of Capnocytophaga, however,
Figure 3 Gram stain from culture of
Capnocytophaga. 1000.
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this pathogen might be underdiagnosed. There-
fore, specimens obtained from percutaneous
aspiration or intraoperatively in patients with
esophageal or pharyngeal perforations should
be transported immediately to the microbiology
laboratory, with special requests for anaerobic
and/or, if possible, micro-aerophilic cultivation,
in order to maximize the detection of Capnocyto-
phaga spp. or other fastidious Gram-negative
bacilli.
Isolation of fastidious bacilli such as Capnocyto-
phaga requires the correct collection of specimens
and appropriate processing. Suspicious material
taken from immunosuppressed patients with
fever of unknown origin should additionally be
cultivated in a CO2-enriched atmosphere. Anae-
robic cultivation should also produce correct
results, but one must be aware that some strains
of Capnocytophaga need more than 2 days to show
growth under anaerobic conditions.
If not treated promptly and appropriately, this
organism is capable of causing sepsis, multi-organ
failure, and eventual death. For this reason, the
physician must take into consideration the possi-
bility of capnocytophaga infection in the setting of
pharyngeal or esophageal injury.
The isolated strains of Capnocytophaga showed
susceptibility to a wide range of antibiotics.
Nevertheless, empirical treatment with second-
generation cephalosporins in combination with
aminoglycosides did not result in clinical improve-
ment in any of our patients. In contrast, a change to
penicillins or carbapenems resulted in immediate
clinical response. Despite the good in vitro sus-
ceptibility of Capnocytophaga, one must take into
consideration the severely impaired defense
mechanisms in these patients, and realize that
response to treatment may be delayed. In the
empirical antibiotic treatment of such infections,
clindamycin, as well as penicillins, should be cho-
sen. Capnocytophaga is resistant to metronidazole,
and despite in vitro susceptibility, cephalosporins
might not prompt a clinical response.
One should also be aware that Capnocytophaga
may exhibit b-lactamase production, resulting in
major problems with resistance [18,19].
In 1994, a cluster of four capnocytophaga infec-
tions was observed in the stem cell transplant unit.
All strains involved in this cluster underwent
confirmation at a reference laboratory, and subse-
quently we performed RFLP in order to exclude
nosocomial spread via the laminar airflow unit
shared by these patients, by hospital staff, or by
hospital equipment. Since all strains were differ-
ent, such a common source was excluded, and
endogenous infection must be suspected. How-
ever, a unique protocol for infection prevention,
including oral decontamination using chlorhexi-
dine rinsing of the oral cavity, non-absorbable
antibiotics (aminoglycoside in combination with
nystatin), and trimethoprim sulfamethoxazole for
pneumolystis carinii pneumonia prophylaxis, was
used. Such a protocol might facilitate overgrowth
of some more resistant microorganisms, thus con-
tributing to the described cases.
Our experience represents the circumstances
under which capnocytophaga infections may
occur and have the potential to be life-threaten-
ing—in patients who are immunocompromised,
for whatever reason, and in patients whose nor-
mally sterile sites have been inoculated with the
colonizing bacteria of the oral cavity, which can
alter host defense [20–22]. Therefore, in such cir-
cumstances, one must maintain a high index of
suspicion for capnocytophaga infection, and fol-
low this up with optimal cultivation, appropriate
microbiological testing, and antibiotic and/or sur-
gical therapy.
Capnocytophaga is an unusual pathogen, causing
severe infections, mainly in the immunocompro-
mised host. Accurate diagnosis and adequate
treatment are of major importance in the manage-
ment of these infections.
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